There were 639 press releases posted in the last 24 hours and 149,047 in the last 365 days.

Global Nicotine Addiction Drugs and Companies Pipeline Review H2 2016

Nicotine Addiction Treatment Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016 / -- The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete Report @

- The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
- The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects
- The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Nicotine Addiction

Get Sample Report @

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @

Table of Content

Therapeutics Development 8
Pipeline Products for Nicotine Addiction - Overview 8
Pipeline Products for Nicotine Addiction - Comparative Analysis 9
Nicotine Addiction - Therapeutics under Development by Companies 10
Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes 11
Nicotine Addiction - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nicotine Addiction - Products under Development by Companies 14
Nicotine Addiction - Products under Investigation by Universities/Institutes 15
Nicotine Addiction - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Astraea Therapeutics, LLC 17
Cerecor Inc. 18
Chronos Therapeutics Limited 19
Embera NeuroTherapeutics, Inc. 20
Hager Biosciences, LLC 21
Heptares Therapeutics Limited 22
Omeros Corporation 23
Nicotine Addiction - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 31
Drug Profiles 33
(metyrapone + oxazepam) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ADX-71441 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
AT-1001 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CERC-501 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
EORA-101 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
OMS-405 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
OMS-527 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecule for Nicotine Addiction - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecule for Psychiatric Disorders - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 50
Product Description 50
Mechanism Of Action 50

Buy now @

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here